)
Edge11 Sep 2026
Texas Pacific Land Corporation: Keeper of the Permian Basin
Land once granted to a failed 19th-century railroad now generates royalties for Texas Pacific Land Corporation across the Permian Basin.
Adaptive Biotechnologies
Adaptive Biotechnologies (ADPT) investor relations material
Adaptive Biotechnologies Morgan Stanley 24th Annual Global Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Morgan Stanley 24th Annual Global Healthcare Conference summary15 Sep, 2026
Key guideline and market updates
NCCN guidelines for multiple myeloma now include a dedicated page for MRD testing, naming clonoSEQ specifically for the first time, which is rare for a test manufacturer.
Guidelines now prefer 10^-6 sensitivity for MRD, aligning with clonoSEQ's capabilities and recommending use at regular intervals during maintenance and surveillance.
Peripheral blood is now recognized for MRD assessment in multiple myeloma, supporting a shift from bone marrow and increasing potential test volumes.
Total addressable market (TAM) was recently increased by $800 million, reflecting more tests per patient per year.
Blood-based testing and serial monitoring are driving higher adoption, especially in community settings, with 36% of volumes now from community practices.
Financial performance and outlook
Clinical volumes and repeat ordering rates are strong, with high compliance in EMR-integrated systems like Flatiron and Epic.
Pharma business momentum is robust, and the company expects to generate free cash flow and EBITDA in Q4.
Guidance for 2023 is 38%-40% growth, with potential upside due to strong adoption and pharma contributions.
Blood-based testing now accounts for 51% of volumes in Q2, increasing the number of tests per patient and expanding market size.
Submission to MolDX aims to increase the number of reimbursed tests per episode, expected to alleviate ASP pressure.
Strategic separation and business focus
A separation of the MRD and immune medicine businesses is planned, driven by maturity and scale in both segments.
MRD is now the core business, generating most revenue and investment, while immune medicine is managed with prudent investment.
The immune medicine business leverages proprietary data and AI for applications like personalized cancer vaccines and target discovery.
By year-end, the company will outline the path forward for the immune medicine business, aiming to maximize shareholder value.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Adaptive Biotechnologies
- Q2 2026 revenue up 22–30%, MRD growth strong, and full-year guidance raised.ADPT
Q2 2026 - MRD and Immune Medicine units drive growth, with profitability targeted by end of 2026.ADPT46th Annual William Blair Growth Stock Conference
- Q1 2026 revenue up 35–45%, MRD grew 53%, net loss narrowed, guidance raised.ADPTQ1 2026
- Virtual meeting to elect directors, approve pay, and ratify auditor on June 5, 2026.ADPTProxy filing
- 2026 meeting to elect directors, approve pay, and ratify auditor amid strong MRD growth.ADPTProxy filing
- MRD diagnostics and immune medicine drive growth, with FY 2026 MRD revenue guided at $255–$265M.ADPTCorporate presentation
- MRD revenue rose 36% year-over-year, margins improved, and guidance was raised.ADPTQ2 2024
- MRD revenue up 52% year-over-year, driving improved margins and a narrowed net loss.ADPTQ3 2024
- MRD revenue surged 34% in Q1 2025, driving raised guidance and improved profitability.ADPTQ1 2025
Next Adaptive Biotechnologies earnings date
Q3 20264 Nov, 2026
Adaptive Biotechnologies
Next Adaptive Biotechnologies earnings date
Q3 20264 Nov, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage